Seeking Alpha

jamesoh

jamesoh
Send Message
View as an RSS Feed
Latest  |  Highest rated
  • Exact Sciences (EXAS) shares could get a lot healthier if its test aimed at early detection of colon cancer really works, Barron's writes. If the trial results, expected early next year, are favorable, the test could hit the market in 2014 and the company's annual revenue could top $500M or even $1B by the end of this decade if the test gains wide acceptance. EXAS +7.5% premarket. [View news story]
    am I right...at 1 billion revenue that computes to 17 cents per share ?
    Oct 8 04:44 PM | Likes Like |Link to Comment
COMMENTS STATS
1 Comment
0 Likes